ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Vir Biotechnology Inc

Vir Biotechnology Inc (VIR)

10.22
-0.05
(-0.49%)
Closed July 18 4:00PM
10.22
0.00
( 0.00% )
Pre Market: 4:01AM

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
10.22
Bid
10.19
Ask
11.00
Volume
6
0.00 Day's Range 0.00
7.61 52 Week Range 23.19
Market Cap
Previous Close
10.22
Open
-
Last Trade
3
@
10.22
Last Trade Time
06:49:22
Financial Volume
-
VWAP
-
Average Volume (3m)
1,185,825
Shares Outstanding
136,058,680
Dividend Yield
-
PE Ratio
-2.26
Earnings Per Share (EPS)
-4.52
Revenue
86.18M
Net Profit
-615.06M

About Vir Biotechnology Inc

Vir Biotechnology Inc is a commercial-stage immunology company focused on treating and preventing infectious diseases. It has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA, through internal development, collaborations, an... Vir Biotechnology Inc is a commercial-stage immunology company focused on treating and preventing infectious diseases. It has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA, through internal development, collaborations, and acquisitions. The company's pipeline consists of product candidates targeting hepatitis B virus, or HBV, influenza A, human immunodeficiency virus, or HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue and license revenue. Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Website
Headquarters
Wilmington, Delaware, USA
Founded
1970
Vir Biotechnology Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker VIR. The last closing price for Vir Biotechnology was $10.22. Over the last year, Vir Biotechnology shares have traded in a share price range of $ 7.61 to $ 23.19.

Vir Biotechnology currently has 136,058,680 shares outstanding. The market capitalization of Vir Biotechnology is $1.39 billion. Vir Biotechnology has a price to earnings ratio (PE ratio) of -2.26.

VIR Latest News

Vir Biotechnology to Report Second Quarter 2024 Financial Results on August 1, 2024

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide financial results for the second quarter ended June 30, 2024, on August 1, 2024. The Company will host a conference...

Vir Biotechnology Receives FDA IND Clearance and Fast Track Designation for Tobevibart and Elebsiran for the Treatment of Chronic Hepatitis Delta Infection

Fast Track designation follows positive preliminary Phase 2 trial data presented at the European Association for the Study of the Liver Congress 2024 and underscores the unmet need for people...

Tobevibart Monotherapy and Combination Therapy with Elebsiran Achieved High Virologic Response and ALT Normalization in People Living with the Hepatitis Delta Virus After 12 and 24 Weeks of Treatment

– Preliminary Phase 2 SOLSTICE trial data reinforce the potential of both regimens to be transformative treatments in an area of high unmet medical need – – Conference call scheduled for June 5...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.899.539121114689.3310.569.20510609569.96185604CS
41.2513.93534002238.9710.568.2512787179.20183726CS
122.4832.04134366937.7413.097.6411858259.89007965CS
260.383.861788617899.8413.097.6111191349.89811638CS
52-12.72-55.448997384522.9423.197.61126095910.3255931CS
156-26.27-71.992326664836.49587.61118345723.06953627CS
260-5.93-36.718266253916.15141.017.61113575029.73016346CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
HUBCWHub Cyber Security Ltd
$ 0.0345
(94.92%)
62
SERVServe Robotics Inc
$ 4.36
(65.78%)
2.29M
UBFOUnited Security Bancshares
$ 12.30
(58.91%)
559
SXTP60 Degrees Pharmaceuticals Inc
$ 0.3291
(33.78%)
5.67M
GNLXGenelux Corporation
$ 2.90
(26.09%)
2
KITTNauticus Robotics Inc
$ 0.1022
(-20.71%)
913.8k
SPWRSunPower Corporation
$ 1.24
(-17.88%)
545.02k
MTEMMolecular Templates Inc
$ 1.21
(-15.38%)
1
WAVDWaveDancer Inc
$ 1.71
(-14.93%)
663
AZA2Z Smart Technologies Corporation
$ 0.7623
(-14.33%)
173
SXTP60 Degrees Pharmaceuticals Inc
$ 0.3291
(33.78%)
5.67M
SGDSafe and Green Development Corporation
$ 0.4615
(24.80%)
5.23M
SQQQProShares UltraPro Short QQQ
$ 8.25
(0.24%)
2.66M
SERVServe Robotics Inc
$ 4.36
(65.78%)
2.29M
MAXNMaxeon Solar Technologies Ltd
$ 0.2321
(-3.45%)
1.82M

VIR Discussion

View Posts
Monksdream Monksdream 2 weeks ago
VIR under $10
👍️0
DewDiligence DewDiligence 1 month ago
VIR +18% on phase-2 HDV data at EASL:

https://finance.yahoo.com/news/tobevibart-monotherapy-combination-therapy-elebsiran-093000369.html

Note: HDV is a subset of HBV insofar as HDV resides within HBV’s capsid.
👍️0
DewDiligence DewDiligence 3 months ago
VIR 1Q24 CC transcript:

https://finance.yahoo.com/news/vir-biotechnology-inc-nasdaq-vir-170535096.html
👍️0
Monksdream Monksdream 3 months ago
VIR still reversing off the recent 52 week low
👍️0
DewDiligence DewDiligence 3 months ago
VIR reports 1Q24 results—3/31/24 cash=$1.51B(!):

https://www.businesswire.com/news/home/20240502260564/en

VIR re-iterated guidance for 2024 operating expenses of $650-680M.

CC slides:
https://investors.vir.bio/files/doc_financials/2024/q1/Vir-Corporate-Presentation_Q1-2024.pdf
👍️0
Monksdream Monksdream 3 months ago
VIR under $10
👍️0
DewDiligence DewDiligence 3 months ago
VIR adds two luminaries to BoD:

https://www.businesswire.com/news/home/20240418098064/en

The capsule bios in the PR speak for themselves.
👍️0
DewDiligence DewDiligence 5 months ago
VIR 4Q23 CC transcript:

https://finance.yahoo.com/news/q4-2023-vir-biotechnology-inc-185403667.html
👍️ 1
DewDiligence DewDiligence 5 months ago
VIR 4Q23 CC slides:

https://investors.vir.bio/files/doc_presentations/2024/02/22/Vir-Corporate-Presentation_Q4-2023.pdf
👍️0
DewDiligence DewDiligence 5 months ago
VIR reports 4Q23 results—issues 2024 expense guidance:

https://www.businesswire.com/news/home/20240222740501/en

12/31/23 cash was $1.63B, after burning $108M during 4Q23.

2024 guidance for SG&A + R&D GAAP expenses is $650-680M.

At the current share price, VIR has an enterprise value of roughly negative $200M.
👍️0
DewDiligence DewDiligence 5 months ago
VIR’s CMO left the company, which explains the exercise-and-hold transaction from January in the post I'm replying to:

https://finance.yahoo.com/news/vir-biotechnology-announces-dr-phil-213000676.html

Note: The above was issued on 2/20/24.
👍️0
DewDiligence DewDiligence 5 months ago
GSK, VIR terminate flu collaboration inked in 2021:

https://www.sec.gov/ixviewer/ix.html?doc=/Archives/edgar/data/0001706431/000162828024006346/vir-20240221.htm

This outcome is not surprising outcome insofar as the phase-2 trial of VIR-2484, the lead compound of the collaboration, was a failure ( #msg-172395320).
👍️0
DewDiligence DewDiligence 6 months ago
VIR’s CMO exercised and held ~$800K of stock yesterday:

https://www.sec.gov/Archives/edgar/data/1706431/000162828024000169/xslF345X05/wk-form4_1704311270.xml

The options in question did not expire until 2027-2028.
👍️0
DewDiligence DewDiligence 7 months ago
VIR cuts workforce 12%:

https://www.businesswire.com/news/home/20231213396441/en

It’s bizarre to see belt-tightening by a company with $1.7B of net cash (https://www.sec.gov/ix?doc=/Archives/edgar/data/0001706431/000162828023036702/vir-20230930.htm#i4ba948c416a6412b946073491455ca74_19 ), but it’s probably the right thing to do inasmuch as the stock’s EV is deeply negative.
👍️0
harry crumb harry crumb 8 months ago
Nice move today
👍️0
DewDiligence DewDiligence 12 months ago
VIR -45% on phase-2 failure in influenza:

https://finance.yahoo.com/news/vir-biotechnology-announces-topline-data-120000102.html Vir Biotechnology…today announced that the Phase 2 PENINSULA trial evaluating VIR-2482 for the prevention of symptomatic influenza A illness did not meet primary or secondary efficacy endpoints. Why such a steep selloff? One reason is that VIR has tended to present itself to investors as all-powerful and all-knowing, which is perhaps a consequence of having George Scangos as (ex)CEO and having raised a huge amount of capital based on management’s reputation.
👍️0
DewDiligence DewDiligence 1 year ago
VIR starts 4-drug phase-2 HBV trial:

https://www.globenewswire.com/news-release/2023/05/11/2666740/0/en/Vir-Biotechnology-Announces-First-Patient-Dosed-in-New-Phase-2-Chronic-Hepatitis-B-Virus-Trial-Evaluating-Combinations-of-VIR-2218-VIR-3434-PEG-IFN%CE%B1-and-an-NRTI.html

The four drugs are: VIR-2218, a siRNA; VIR-3434, a mAb; PEG-IFN; and a (generic) nucleoside.

A separate phase-2 trial (VIR calls it a “subprotocol”) will test VIR-3434 and a nuke, with and without VIR-2218, in patients who are chronic inactive carriers of the HBV virus. I'm unclear as to whether this second trial is for research purposes or for an addressable commercial market.
👍️0
DewDiligence DewDiligence 2 years ago
48w VIR-2219 +peg-IFN—>31% HBs seroconverion:

https://www.globenewswire.com/news-release/2022/11/06/2549180/0/en/Vir-Biotechnology-Presents-New-Data-Evaluating-the-Potential-for-VIR-2218-and-VIR-3434-to-Achieve-a-Functional-Cure-for-Chronic-Hepatitis-B-Virus-HBV-Infection.html

The 31% figure is impressive insofar as peg-IFN by itself has a 48w seroconversion rate of only 5-10%. Of course, a 48w regimen of VIR-2219 + peg-IFN won’t be any easier to tolerate than 48w of peg-IFN monotherapy, so this regimen is still far from the ultimate answer for treating chronic HBV.

VIR has started testing the triple combination of VIR-2219 (siRNA) + VIR-3434 (mAb) + peg-IFN; initial data are expected in 2H23.
👍️0
DewDiligence DewDiligence 2 years ago
VIR EASL presentations:

https://www.globenewswire.com/news-release/2022/06/25/2469082/0/en/Vir-Biotechnology-Announces-New-Clinical-Data-From-its-Broad-Hepatitis-B-Program.html

No CC.
👍️0
DewDiligence DewDiligence 2 years ago
VIR HBV webcast slides:

https://investors.vir.bio/static-files/7ece44c3-0585-47af-81b4-2199889d6934
👍️0
DewDiligence DewDiligence 2 years ago
VIR -14% on amended Sotrovimab EUA due to Omicron BA.2 variant:

https://finance.yahoo.com/news/us-food-drug-administration-revises-200400156.html GlaxoSmithKline plc and Vir Biotechnology…today announced that the US Food and Drug Administration has amended the Emergency Use Authorization (EUA) Fact Sheet for sotrovimab, an investigational monoclonal antibody. The FDA has determined that, based on the totality of available evidence, including new live virus data generated by Vir, it is unlikely that the sotrovimab 500 mg dose will be effective against the Omicron BA.2 variant.

GSK and Vir are preparing a package of data in support of a higher dose of sotrovimab for the Omicron BA.2 subvariant and will be sharing these data with regulatory and health authorities around the world for discussion. This PR was issued after the close, but the market apparently got wind of the FDA decision about 3:45pm ET.
👍️0
DewDiligence DewDiligence 2 years ago
VIR 4Q21 results:

https://www.globenewswire.com/news-release/2022/02/24/2391890/0/en/Vir-Biotechnology-Provides-Corporate-Update-and-Reports-Fourth-Quarter-and-Full-Year-2021-Financial-Results.html As of December 31, 2021, excluding restricted cash, the Company had approximately $909.5 million in cash, cash equivalents, and investments. Excluding restricted cash and its equity investment in Brii Biosciences, the Company had approximately $766.4 million in cash, cash equivalents and investments.
👍️0
DewDiligence DewDiligence 2 years ago
VIR’s 2022 HBV newsflow:

https://www.globenewswire.com/news-release/2022/02/24/2391890/0/en/Vir-Biotechnology-Provides-Corporate-Update-and-Reports-Fourth-Quarter-and-Full-Year-2021-Financial-Results.html In 2022, the Company expects data readouts from multiple trials evaluating VIR-2218 and VIR-3434:

• Initial data from the first cohorts of Phase 2 MARCH (Monoclonal Antibody siRNA Combination against Hepatitis B) trial of VIR-2218 in combination with VIR-3434, are expected in the first half of 2022.

• Additional data from the Phase 2 trial of VIR-2218 in combination with PEG-IFN-alpha are expected in the first half of 2022.

• Additional data from the Phase 1 monotherapy trial of VIR-3434 are expected in the first half of 2022.

• The Company’s collaborator, Brii Biosciences, continues to lead the Phase 2 trial evaluating VIR-2218 in combination with BRII-179, an investigational T cell vaccine, for the potential treatment of chronic HBV infection. Initial data are expected in the second half of 2022. Evidently, there will not be a 2022 readout from the phase-2 trial testing combinations of VIR-2218, GILD’s GS-9688, Vemlidy (TAF), and Opdivo (#msg-167061759, #msg-160854272, #msg-167063133).
👍️0
rwwest rwwest 2 years ago
Up so far on another Biotech down day
Seems like a good omen.
👍️0
DewDiligence DewDiligence 3 years ago
VIR slide set from JPM:

https://investors.vir.bio/static-files/7ecf45fb-6918-4cf8-9a02-b8c12183ca4f
👍️0
DewDiligence DewDiligence 3 years ago
VIR/GILD start phase-2 trial testing quadruple regimen of VIR-2218; GS-9688; Opdivo; and Vemlidy (TAF) in (both nuc-suppressed and viremic) HBV patients:

https://finance.yahoo.com/news/vir-biotechnology-announces-initiation-phase-133000267.html

I’m not sure why it took almost a year for this trial to begin enrolling patients—the PR announcing the collaboration was issued on 1/12/21.

Please see #msg-160854272 for background.
👍️0
HokieHead HokieHead 3 years ago
Loaded again. After omicron news all weekend this will be the next MRNA biotech. $75+ by years end for starters imo.
👍️0
HokieHead HokieHead 3 years ago
In $46, omicron play.
👍️0
DewDiligence DewDiligence 3 years ago
VIR starts HBV_combination_trial_of_ VIR-2218 and VIR-3434:

https://finance.yahoo.com/news/vir-biotechnology-initiates-phase-2-123000780.html The multi-center, open-label Phase 2 trial is designed to evaluate the safety, tolerability and efficacy of the combination of VIR-2218 and VIR-3434 in approximately 90 adult patients (ages 18 to 65) with chronic HBV infection receiving nucleot(s)ide reverse transcriptase inhibitor therapy. Both VIR-2218 and VIR-3434 will be administered via subcutaneous injection at varying dose levels over the course of the trial for a treatment period ranging from four to 20 weeks, and a follow-up period of up to 116 weeks, depending on the dosing cohort.

…VIR-2218 is an investigational small interfering ribonucleic acid (siRNA) designed to inhibit the production of all HBV proteins (X, polymerase, S and core), which may be acting as immune tolerogens. VIR-3434 is an investigational HBV-neutralizing monoclonal antibody designed to block entry of all 10 genotypes of HBV into hepatocytes, as well as reduce the level of virions and subviral particles in the blood. It has also been Fc engineered to include the XX2 “vaccinal mutation,” allowing it to potentially function as a therapeutic T cell vaccine against HBV. See #msg-164593550, #msg-161217289, and #msg-164599741 for related info.
👍️0
DewDiligence DewDiligence 3 years ago
VIR -6% on VIR-2218 and VIR-3434 monotherapy data presented at EASL:

https://finance.yahoo.com/news/vir-biotechnology-presents-clinical-data-125000851.html

CC to discuss these data with investment community at 11am ET.
👍️0
level42 level42 3 years ago
"profound efficacy." Vir Biotechnology and GSK plan to seek emergency use authorization for their experimental COVID-19 antibody therapy after interim data from a study showed 85% reduction in hospitalization and deaths among patients.


Based on these positive results, Vir and GlaxoSmithKline intend to request Emergency Use Authorization (EUA) for VIR-7831 from the U.S. Food and Drug Administration (FDA) and other international regulators.

"We are pleased that this unique monoclonal antibody was able to bring such a profound benefit to patients," GlaxoSmithKline chief scientific officer Dr. Hal Barron said. "We look forward to the possibility of making VIR-7831 available to patients as soon as possible."
👍️0
interloper interloper 3 years ago
Too high too fast. Very typical price movement. I you think your gonna ride a rocket to the moon you better be ready when the booster fuel runs out.
👍️0
dealerschool2006 dealerschool2006 3 years ago
why is VIR coming back down???
👍️0
rtrstock rtrstock 3 years ago
Huge disappointment.

This could go back to under 20.00 pps

Should have sold at 140.00

This stock price is just based on hype, the collapse is the reality of things.

👍️0
CatBirdSeat CatBirdSeat 3 years ago
Two New Rockships Taking Off After VIR

Behold! FNMA & FMCC

Ka Ching ! Baby! $$$$
👍️0
rtrstock rtrstock 3 years ago
I Should have sold at 140.00

Now it's in a death spiral.

Robinhood shows this listing at a completely different price than ihub.
👍️0
Srhogan1984 Srhogan1984 3 years ago
Full of crap haha
👍️0
ClayTrader ClayTrader 3 years ago
* * $VIR Video Chart 01-26-2021 * *

Link to Video - click here to watch the technical chart video

👍️0
Srhogan1984 Srhogan1984 3 years ago
Sounds like a short to me. You need a bog squeeze? Haha
👍️0
DewDiligence DewDiligence 3 years ago
Today's move is somewhat scary in the context of #msg-160142077.
👍️0
DewDiligence DewDiligence 3 years ago
VIR—(+40% undeservedly, IMO)—on_interim_phase-1_data_for VIR-3434_in_HBV:

https://www.globenewswire.com/news-release/2021/01/26/2164220/0/en/Initial-Data-from-Ongoing-Phase-1-Trial-of-VIR-3434-for-Chronic-Hepatitis-B-Virus-Infection-Demonstrates-Significant-and-Rapid-Reduction-in-Hepatitis-B-Surface-Antigen.html

The mean reduction in HBsAg (n=6) was 1.3 logs after 8 days. That’s not bad, but neither is it a knock-your-socks-off result. Monotherapy is unlikely to generate a functional cure in HBV, no matter how potent the agent may be against HBsAg.

VIR-3434 is a monoclonal antibody and is VIR’s second HBV agent in the clinic; the first is VIR-2218, an RNAi agent (#msg-155042587).
👍️0
DewDiligence DewDiligence 4 years ago
Not really. It's just a phase-2 trial, not a full-fledged partnership.
👍️0
DewDiligence DewDiligence 4 years ago
GILD, VIR collaborate on phase-2 HBV trial:

https://www.businesswire.com/news/home/20210112005578/en The companies plan to initiate a Phase 2 trial evaluating combination therapy for both treatment-experienced and treatment-naïve people living with HBV. The multi-arm trial will evaluate different combinations of selgantolimod, Gilead’s investigational TLR-8 agonist; VIR-2218, Vir’s investigational small interfering ribonucleic acid (siRNA); and a commercially-sourced, marketed PD-1 antagonist. People in the trial with HBV treatment experience may also receive Gilead’s Vemlidy (tenofovir alafenamide fumarate, TAF). The primary outcome of the study will be the proportion of patients achieving a functional cure, defined as an off-therapy loss of hepatitis B surface antigen (HBsAg) and HBV DNA from the serum.

Both companies retain full rights to their individual product candidates and will discuss the potential path forward for any future combination studies based on the outcome of the Phase 2 trial. I.e., no cash is changing hands between the two companies.
👍️0
Srhogan1984 Srhogan1984 4 years ago
Huge news!
👍️0
Srhogan1984 Srhogan1984 4 years ago
What is happening here
👍️0
DewDiligence DewDiligence 4 years ago
VIR starts phase-1 trial of VIR-3434:

https://www.globenewswire.com/news-release/2020/05/27/2039353/0/en/Vir-Biotechnology-Initiates-Phase-1-Clinical-Trial-of-VIR-3434-for-Chronic-Hepatitis-B-Virus-Infection.html
👍️0
ClayTrader ClayTrader 4 years ago
* * $VIR Video Chart 05-18-2020 * *

Link to Video - click here to watch the technical chart video

👍️0
DewDiligence DewDiligence 4 years ago
VIR 1Q20 results—3/31/20 cash=$361.8M:

https://www.globenewswire.com/news-release/2020/05/12/2032224/0/en/Vir-Biotechnology-Provides-Corporate-Update-and-Reports-First-Quarter-2020-Financial-Results.html
👍️0
DewDiligence DewDiligence 4 years ago
VIR reports interim phase-2 data in HBV:

https://finance.yahoo.com/news/vir-2218-demonstrates-dose-dependent-200110652.html Vir Biotechnology today announced additional interim data from the ongoing Phase 2 trial… of VIR-2218, an investigational small interfering ribonucleic acid (siRNA) that mediates RNA interference (RNAi) for the treatment of chronic hepatitis B virus (HBV) infection.

…In the ongoing Phase 2 trial, virally suppressed patients on nucleos(t)ide reverse transcriptase inhibitor therapy (n=24) received two subcutaneous 20, 50, 100, or 200 mg doses of VIR-2218 on Day 1 and Day 29. At Week 24, the mean change in HBsAg observed with 20, 50, 100, and 200 mg was -0.76 log10, -0.93 log10, -1.23 log10, and -1.43 log10, respectively [a nice dose response].

Of note, all patients who received the 200 mg dose level achieved a >=1 log10 reduction in HBsAg, with HBeAg- and HBeAg+ patients achieving similar mean declines. There has been no dose-related trend in the frequency of AEs observed during the trial, with the most common AE being headache (n=6; 25%). No patients discontinued the trial due to an AE.

…“Our next step will be to demonstrate whether knockdown of HbsAg can result in high rates of functional cure when VIR-2218 is given in combination with other agents, which is the goal of our next set of trials. We expect the first of those combination trials—combining VIR-2218 with a shortened course of pegylated interferon—to begin dosing patients in the second half of this year.” VIR-2218 incorporates ALNY’s ESC+ siRNA technology, which VIR claims is a differentiating factor for VIR-2218 compared to other RNAi-based programs in HBV.

CC slides for the above data:
https://investors.vir.bio/static-files/48b8fe3c-79cb-4a80-85e9-ba1f14682abd

VIR is flattish in AH trading, but this doesn’t mean much vis-à-vis the HBV data presented above; lately, VIR has been trading as a COVID-19 play.
👍️0
Cornball69 Cornball69 4 years ago
nobody pumping this here lol?
👍️0

Your Recent History

Delayed Upgrade Clock